▶ 調査レポート

除細動器の世界市場:エンドユーザー別、製品別、地域別分析

• 英文タイトル:Global Defibrillator Market- Segmented by End User, Product, and Geography - Growth, Trends, and Forecast (2018 - 2023)

が調査・発行した産業分析レポートです。除細動器の世界市場:エンドユーザー別、製品別、地域別分析 / Global Defibrillator Market- Segmented by End User, Product, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-06003資料のイメージです。• レポートコード:B-MOR-06003
• 出版社/出版日: / 2018年6月20日
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥629,000 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥666,000 (USD4,500)▷ お問い合わせ
  Corporate User¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、除細動器の世界市場について調べ、除細動器の世界規模、市場動向、市場環境、エンドユーザー別分析、製品別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・除細動器の世界市場インサイト
・除細動器の世界市場環境
・除細動器の世界市場動向
・除細動器の世界市場規模
・除細動器の世界市場規模:エンドユーザー別
・除細動器の世界市場規模:製品別
・除細動器の世界市場:地域別市場規模・分析
・除細動器の北米市場規模・予測
・除細動器のアメリカ市場規模・予測
・除細動器のヨーロッパ市場規模・予測
・除細動器のアジア市場規模・予測
・関連企業情報・競争状況

The global defibrillator market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. Defibrillator is a life-saving device that helps deliver a therapeutic shock to a patient’s heart in life-threatening conditions, such as ventricular fibrillation, cardiac arrhythmia, and pulseless ventricular tachycardia. In the United States, approximately 300,000 out-of-hospital cardiac arrests occur each year. Supportive government policies in developed countries may help increase the availability and access of defibrillators, which will further boost the market growth over the forecast period.

Increase in the Prevalence Rate of Cardio Vascular Diseases
According to the American Heart Association’s research program, cardiovascular diseases are listed as the primary cause of deaths and accounted for nearly 836,546 deaths in the United States.. The deaths related to cardiovascular diseases are higher when compared to deaths related to all forms of cancer and chronic lower respiratory diseases combined. As per the American Heart Association, cardiovascular disease is the leading cause of death, globally, accounting for more than 17.9 million deaths per year in 2015, a number that is expected to grow to more than 23.6 million by 2030. Hence, the increase in prevalence of cardiovascular diseases is expected to drive the market growth.
Other factors driving this market are technological advancements in the field of defibrillators and training and awareness programs for defibrillators.

Stringent Regulatory Framework
Defibrillators face stricter regulations when compared to other devices of this category, which is one of the major factors that may hinder the growth of the market. For instance, in 2015, the US FDA ordered the PMA approval for new and existing automated external defibrillators, citing manufacturing issues, and recalled more than 2 million devices since 2005. Also, the rise in product failure, recalls, and the lack of awareness about SCA, especially in the emerging markets, are expected to hamper the market growth.
Other factors that may restraint the market include: high costs of the defibrillators.

North America to Dominate this Market
Cardiovascular diseases, listed as the underlying cause of death, account for nearly 836,546 deaths (about 1 of every 3 deaths) in the United States. Thus, the increasing prevalence of cardiovascular diseases in the region is expected to drive the growth of this market over the forecast period. In 2017, the Department of Health and Human Services (HHS), along with a number of public and private partners, launched the Million Hearts initiative that aims to prevent one million heart attacks and strokes. All the aforementioned factors are expected to boost the market growth.

Key Developments in the Market
• May 2018: Medtronic PLC announced results from a research study demonstrating the feasibility of a novel approach in delivering pacing and defibrillation therapy in which a lead is placed under the sternum (breastbone), outside the heart and veins.
• February 2017: Boston Scientific Europe announced the launch of RESONATE cardiac resynchronisation therapy defibrillator (CRT-D) systems in Europe, a new family of devices featuring SmartCRT technology, which recently received CE Mark and are now available for heart failure patients across Europe.

Major Players: BOSTON SCIENTIFIC CORPORATION, CARDIAC SCIENCE, DEFIBTECH LLC, KONINKLIJKE PHILIPS NV, LIVANOVA PLC, MEDTRONIC, NIHON KOHDEN CORPORATION, PHYSIO-CONTROL INC., ABBOTT (ST. JUDE MEDICAL, LLC), and ZOLL MEDICAL CORPORATION, amongst others.

Reasons to Purchase this Report
• Current and future global defibrillator market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Pipeline Analysis
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Consumers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitute Product and Services
5.3.5 Competitive Rivalry within the Industry
5.4 Regulatory Screnario
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Prevalence of Cardiovascular Diseases
6.1.2 Technological Advancements in the Field of Defibrillators
6.1.3 Training and Awareness Programs about Defibrillators
6.2 Market Restraints
6.2.1 High Costs of Defibrilators
6.2.2 Stringent Regulatory Framework
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By End User
7.1.1 Hospitals
7.1.2 Emergency Care
7.1.3 Home Care
7.1.4 Others
7.2 By Product
7.2.1 Implantable Cardioverter Defibrillator (ICD)
7.2.1.1 Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
7.2.1.2 Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
7.2.1.3 CRT with pacemaker and ICD function (CRT-D)
7.2.2 External Defibrillator (ED)
7.2.2.1 Automated External Defibrillator (AEDs)
7.2.2.1.1 Semi-automated External Defibrillators
7.2.2.1.2 Fully Automated External Defibrillators
7.2.2.2 Manual External Defibrillator
7.2.2.3 Wearable Cardioverter Defibrillators (WCDs)
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest Of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Boston Scientific Corporation
9.2 Cardiac Science
9.3 Defibtech LLC
9.4 Koninklijke Philips NV
9.5 LivaNova PLC
9.6 Medtronic
9.7 Nihon Kohden Corporation
9.8 Physio-Control Inc.
9.9 Abbott (St. Jude Medical, LLC)
9.10 ZOLL Medical Corporation
* List Not Exhaustive
10. Future of the Market